Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
EXEL
EXEL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
EXEL News
Exelixis Aims to Expand Beyond Cabozantinib Franchise
Feb 28 2026
NASDAQ.COM
Exelixis Aims to Become a Top Oncology Player with Expanding Pipeline
Feb 28 2026
Fool
Global Oncology Market Expected to Reach $748.17 Billion
Feb 24 2026
PRnewswire
Global Oncology Market Expected to Reach $748.17 Billion
Feb 24 2026
Newsfilter
Exelixis Growth Potential Analysis
Feb 20 2026
Fool
Exelixis Posts Strong Earnings—Could New Highs Be on the Horizon?
Feb 12 2026
Marketbeat
Exelixis Q4 2025 Earnings Call Highlights
Feb 11 2026
seekingalpha
EXELIXIS Q4 ADJUSTED EPS REACHES USD 0.94, BEATING IBES ESTIMATE OF USD 0.79
Feb 10 2026
moomoo
Exelixis Q4 Earnings Beat Expectations with Strong Guidance
Feb 10 2026
seekingalpha
Exelixis Set to Announce Q4 Earnings on February 10th
Feb 09 2026
seekingalpha
Exelixis' NDA for Zanzalintinib Accepted by FDA for Review
Feb 02 2026
Newsfilter
Exelixis and Summit Therapeutics: Promising Drug Candidates Ahead
Feb 01 2026
NASDAQ.COM
Exelixis and Summit Therapeutics: Future Prospects
Feb 01 2026
Fool
Wall Street Analysts Adjust Ratings
Jan 27 2026
Benzinga
10 Healthcare Stocks with A+ EPS Revision Ratings Attracting Investor Attention
Jan 16 2026
seekingalpha
Exelixis Reports Preliminary 2025 Revenue of $2.123 Billion, Shares Drop 4.6%
Jan 12 2026
Benzinga
Show More News
